Microviable Therapeutics — Seed (estimated) · €1.5M

Microviable Therapeutics raised €1.5M from the Madrid medical group Inmunomet to move its microbiota-derived biotherapeutics, including lead candidate MVT-201, towards the clinic. The company later said it planned a round of more than €5M, but no close has been reported. Its 2026 Eurostars-3 funding, co-financed by CDTI and Horizon Europe, is a grant and not a round. PitchBook also lists Capsa Vida and PADEInvest Group as investors, but no announcement confirms that they took part in this round.